Lates News

According to the news on the Novartis Group's WeChat official account on May 29th, Novartis China announced that its oral monotherapy, Feiheida (ipilimumab hydrochloride capsule), has been approved by the National Medical Products Administration (NMPA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adult patients. This expansion of indications covers PNH patients who have already received complement inhibitor therapy. Feiheida's approved indications in China have also increased to three, including adult PNH patients who have not previously received complement inhibitor therapy and adults with C3 glomerulopathy (C3G) (21st Century Business Herald).